Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients

Ryuji Nohara, Hiroyuki Daida, Mitsumasa Hata, Kohei Kaku, Ryuzo Kawamori, Junji Kishimoto, Masahiko Kurabayashi, Izuru Masuda, Ichiro Sakuma, Tsutomu Yamazaki, Hiroyoshi Yokoi, Masayuki Yoshida

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: A recent trial in Western countries has shown that rosuvastatin slows progression of carotid intimamedia thickness (IMT) in patients with modest carotid IMT thickening and elevated levels of low-density lipoprotein cholesterol (LDL-C). We conducted a prospective, randomized, open-label, blinded-endpoint trial to determine whether rosuvastatin is more effective than pravastatin in slowing progression of carotid IMT in Japanese patients. Methods and Results: Adult patients with hypercholesterolemia who had a maximum IMT ≥?1.1 mm were randomly assigned to receive rosuvastatin or pravastatin. The primary endpoint was the percent change in the mean-IMT, which was measured by a single observer who was blinded to the treatment assignments. The trial was stopped on April 2011 according to the recommendation by the data and safety monitoring committee. A total of 348 patients (173 rosuvastatin; 175 pravastatin) were enrolled and 314 (159 rosuvastatin; 155 pravastatin) were included in the primary analysis. Mean (SD) percentage changes in the mean-IMT at 12 months were 1.91% (10.9) in the rosuvastatin group and 5.8% (12.0) in the pravastatin group, with a difference of 3.89% (11.5) between the groups (P=0.004). At 12 months, 85 patients (59.4%) in the rosuvastatin group achieved a LDL-C/high-density lipoprotein cholesterol ratio ≤ 1.5 compared with 24 patients (16.4%) in the pravastatin group (P<0.0001). Conclusions: Rosuvastatin significantly slowed progression of carotid IMT at 12 months compared with pravastatin.

Original languageEnglish
Pages (from-to)221-229
Number of pages9
JournalCirculation Journal
Volume76
Issue number1
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Carotid Intima-Media Thickness
Pravastatin
Lipids
Therapeutics
LDL Cholesterol
Clinical Trials Data Monitoring Committees
Rosuvastatin Calcium
Hypercholesterolemia
HDL Cholesterol
Safety

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients. / Nohara, Ryuji; Daida, Hiroyuki; Hata, Mitsumasa; Kaku, Kohei; Kawamori, Ryuzo; Kishimoto, Junji; Kurabayashi, Masahiko; Masuda, Izuru; Sakuma, Ichiro; Yamazaki, Tsutomu; Yokoi, Hiroyoshi; Yoshida, Masayuki.

In: Circulation Journal, Vol. 76, No. 1, 01.01.2012, p. 221-229.

Research output: Contribution to journalArticle

Nohara, R, Daida, H, Hata, M, Kaku, K, Kawamori, R, Kishimoto, J, Kurabayashi, M, Masuda, I, Sakuma, I, Yamazaki, T, Yokoi, H & Yoshida, M 2012, 'Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients', Circulation Journal, vol. 76, no. 1, pp. 221-229. https://doi.org/10.1253/circj.CJ-11-0887
Nohara, Ryuji ; Daida, Hiroyuki ; Hata, Mitsumasa ; Kaku, Kohei ; Kawamori, Ryuzo ; Kishimoto, Junji ; Kurabayashi, Masahiko ; Masuda, Izuru ; Sakuma, Ichiro ; Yamazaki, Tsutomu ; Yokoi, Hiroyoshi ; Yoshida, Masayuki. / Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients. In: Circulation Journal. 2012 ; Vol. 76, No. 1. pp. 221-229.
@article{aa37cfeacbe84d29a36b422e2f8bca4b,
title = "Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients",
abstract = "Background: A recent trial in Western countries has shown that rosuvastatin slows progression of carotid intimamedia thickness (IMT) in patients with modest carotid IMT thickening and elevated levels of low-density lipoprotein cholesterol (LDL-C). We conducted a prospective, randomized, open-label, blinded-endpoint trial to determine whether rosuvastatin is more effective than pravastatin in slowing progression of carotid IMT in Japanese patients. Methods and Results: Adult patients with hypercholesterolemia who had a maximum IMT ≥?1.1 mm were randomly assigned to receive rosuvastatin or pravastatin. The primary endpoint was the percent change in the mean-IMT, which was measured by a single observer who was blinded to the treatment assignments. The trial was stopped on April 2011 according to the recommendation by the data and safety monitoring committee. A total of 348 patients (173 rosuvastatin; 175 pravastatin) were enrolled and 314 (159 rosuvastatin; 155 pravastatin) were included in the primary analysis. Mean (SD) percentage changes in the mean-IMT at 12 months were 1.91{\%} (10.9) in the rosuvastatin group and 5.8{\%} (12.0) in the pravastatin group, with a difference of 3.89{\%} (11.5) between the groups (P=0.004). At 12 months, 85 patients (59.4{\%}) in the rosuvastatin group achieved a LDL-C/high-density lipoprotein cholesterol ratio ≤ 1.5 compared with 24 patients (16.4{\%}) in the pravastatin group (P<0.0001). Conclusions: Rosuvastatin significantly slowed progression of carotid IMT at 12 months compared with pravastatin.",
author = "Ryuji Nohara and Hiroyuki Daida and Mitsumasa Hata and Kohei Kaku and Ryuzo Kawamori and Junji Kishimoto and Masahiko Kurabayashi and Izuru Masuda and Ichiro Sakuma and Tsutomu Yamazaki and Hiroyoshi Yokoi and Masayuki Yoshida",
year = "2012",
month = "1",
day = "1",
doi = "10.1253/circj.CJ-11-0887",
language = "English",
volume = "76",
pages = "221--229",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "1",

}

TY - JOUR

T1 - Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients

AU - Nohara, Ryuji

AU - Daida, Hiroyuki

AU - Hata, Mitsumasa

AU - Kaku, Kohei

AU - Kawamori, Ryuzo

AU - Kishimoto, Junji

AU - Kurabayashi, Masahiko

AU - Masuda, Izuru

AU - Sakuma, Ichiro

AU - Yamazaki, Tsutomu

AU - Yokoi, Hiroyoshi

AU - Yoshida, Masayuki

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background: A recent trial in Western countries has shown that rosuvastatin slows progression of carotid intimamedia thickness (IMT) in patients with modest carotid IMT thickening and elevated levels of low-density lipoprotein cholesterol (LDL-C). We conducted a prospective, randomized, open-label, blinded-endpoint trial to determine whether rosuvastatin is more effective than pravastatin in slowing progression of carotid IMT in Japanese patients. Methods and Results: Adult patients with hypercholesterolemia who had a maximum IMT ≥?1.1 mm were randomly assigned to receive rosuvastatin or pravastatin. The primary endpoint was the percent change in the mean-IMT, which was measured by a single observer who was blinded to the treatment assignments. The trial was stopped on April 2011 according to the recommendation by the data and safety monitoring committee. A total of 348 patients (173 rosuvastatin; 175 pravastatin) were enrolled and 314 (159 rosuvastatin; 155 pravastatin) were included in the primary analysis. Mean (SD) percentage changes in the mean-IMT at 12 months were 1.91% (10.9) in the rosuvastatin group and 5.8% (12.0) in the pravastatin group, with a difference of 3.89% (11.5) between the groups (P=0.004). At 12 months, 85 patients (59.4%) in the rosuvastatin group achieved a LDL-C/high-density lipoprotein cholesterol ratio ≤ 1.5 compared with 24 patients (16.4%) in the pravastatin group (P<0.0001). Conclusions: Rosuvastatin significantly slowed progression of carotid IMT at 12 months compared with pravastatin.

AB - Background: A recent trial in Western countries has shown that rosuvastatin slows progression of carotid intimamedia thickness (IMT) in patients with modest carotid IMT thickening and elevated levels of low-density lipoprotein cholesterol (LDL-C). We conducted a prospective, randomized, open-label, blinded-endpoint trial to determine whether rosuvastatin is more effective than pravastatin in slowing progression of carotid IMT in Japanese patients. Methods and Results: Adult patients with hypercholesterolemia who had a maximum IMT ≥?1.1 mm were randomly assigned to receive rosuvastatin or pravastatin. The primary endpoint was the percent change in the mean-IMT, which was measured by a single observer who was blinded to the treatment assignments. The trial was stopped on April 2011 according to the recommendation by the data and safety monitoring committee. A total of 348 patients (173 rosuvastatin; 175 pravastatin) were enrolled and 314 (159 rosuvastatin; 155 pravastatin) were included in the primary analysis. Mean (SD) percentage changes in the mean-IMT at 12 months were 1.91% (10.9) in the rosuvastatin group and 5.8% (12.0) in the pravastatin group, with a difference of 3.89% (11.5) between the groups (P=0.004). At 12 months, 85 patients (59.4%) in the rosuvastatin group achieved a LDL-C/high-density lipoprotein cholesterol ratio ≤ 1.5 compared with 24 patients (16.4%) in the pravastatin group (P<0.0001). Conclusions: Rosuvastatin significantly slowed progression of carotid IMT at 12 months compared with pravastatin.

UR - http://www.scopus.com/inward/record.url?scp=84255172397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84255172397&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-11-0887

DO - 10.1253/circj.CJ-11-0887

M3 - Article

VL - 76

SP - 221

EP - 229

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 1

ER -